Teva ups dosage to $2.1bn as investors gulp down pharma bond

By Karoliina Liimatainen
21 Nov 2019

Teva, the Israeli-US pharmaceutical company, priced a $2.1bn bond package at the tighter end of the initial price thoughts this week. While it is yet to come to a settlement over its alleged involvement in the US opioid crisis, investors were happy to jump aboard a rare double-B issue yielding up to 7%.

Teva intended to issue $1.5bn of 2025 senior unsecured notes, but it increased the deal’s size to $2bn and finally to $2.1bn — implying strong demand from investors on both sides of the Atlantic. The issue was split into €1bn and $1bn tranches.

The initial price talk was at mid-to-high ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.